SEPTEMBER 8, 2020 | SOURCE: LABCORP
Single Test Detects Multiple Respiratory Infections Including COVID-19 and Flu to Inform Treatment Options
At-Home Use Through Pixel by LabCorp™Pending FDA Authorization
BURLINGTON, N.C. - LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the launch of the first testing method to simultaneously detect COVID-19, influenza A / B, and respiratory syncytial virus (RSV). The single-panel test, which detects multiple types of infections, can help doctors diagnose patients and make decisions about treatment options. The test is available to patients through doctors, hospitals, and other authorized healthcare providers nationwide. LabCorp has also submitted an application to the U.S. Food and Drug Administration (FDA) to offer the combined test through its Pixel by LabCorp™ at-home test collection kit, which would offer added convenience and accessibility.